Related Experiment Video
Updated: Apr 24, 2026

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
Serum metabolomic biomarkers of dementia
Malahat Mousavi1, Pär Jonsson2, Henrik Antti2
1Department of Integrative Medical Biology, Umeå University, Stockholm, Sweden ; Institute of Environmental Medicine, Stockholm, Sweden.
Aims:
This study compared serum metabolites of demented patients (Alzheimer's disease and vascular dementia) and controls, and explored serum metabolite profiles of nondemented individuals 5 years preceding the diagnosis.
Methods:
Cognitively healthy participants were followed up for 5-20 years. Cognitive assessment, serum sampling, and diagnosis were completed every 5 years. Multivariate analyses were conducted on the metabolite profiles generated by gas chromatography/time-of-flight mass spectrometry.
Results:
A significant group separation was found between demented patients and controls, and between incident cases and controls. Metabolites that contributed in both analyses were 3,4-dihydroxybutanoic acid, docosapentaenoic acid, and uric acid.
Conclusions:
Serum metabolite profiles are altered in demented patients, and detectable up to 5 years preceding the diagnosis. Blood sampling can make an important contribution to the early prediction of conversion to dementia.
More Related Videos
Related Concept Videos
Dementia l: Introduction
Dementia
The progression of dementia is generally gradual....
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer Disease l: Introduction

